Skip to content

Investigating Periprosthetic Fracture Cultures in Arthroplasty

Investigating Periprosthetic Fracture Culture Positivity in Patients With Hip and Knee Arthroplasties

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06952738
Enrollment
200
Registered
2025-05-01
Start date
2025-10-01
Completion date
2027-10-31
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periprosthetic Fracture Around Prosthetic Joint Implant

Keywords

Periprosthetic fractures, synovial fluid, prosthetic joint infections

Brief summary

This study aims to improve how doctors diagnose infections in patients with broken bones around joint replacements. Currently, there are no clear guidelines to help determine when an infection is present, making treatment decisions difficult. By studying how often infections are found through lab tests and identifying factors that predict infection, the investigators hope to create better ways to diagnose and care for these patients.

Detailed description

All steps in the protocol will be completed under the standard of care for our hospital's orthopedic joints and trauma surgeons. All patients identified under the inclusion criteria will undergo preoperative imaging. In accordance with current standards of care, patients with periprosthetic fractures (PPFs) around the hip will receive three views of X-rays of the hip and femur as well as the anterior-posterior view of the pelvis. Likewise, patients with PPFs around the knee will undergo X-rays that include the knee and femur. No advanced imaging (Computed Tomography, Magnetic Resonance Imaging, etc.) will be obtained for the purpose of this study. Preoperative laboratory analysis will include C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammatory markers. Intraoperative synovial fluid analysis will be performed using synovial white blood cell (WBC) count and polymorphonuclear (PMN) percentage. Three cultures will be obtained from the involved joint fluid and tissue, and incubated for 14 days for analysis of aerobic, anaerobic bacterial cultures, fungal and acid-fast bacilli (AFB) analysis. The cultures will be collected from synovial fluid, peri-implant femoral synovium/periosteum, peri-implant tibial or acetabular synovium/periosteum. These laboratory tests and cultures are part of the standard protocol our surgeons have determined for their patient care. Based on the Musculoskeletal Infection Society (MSIS) criteria for positive histology intraoperative histology will be performed utilizing frozen section analysis. These slides will be isolated from synovium, peri-implant femoral synovium/periosteum, and peri-implant tibial or acetabular synovium/periosteum. Additional cultures may be sent at discretion of surgeon but would not be included in analysis. Per institutional protocol, preoperative cefazolin and vancomycin will be administered intravenously and continued for 24 hours perioperatively. Patients who are allergic to vancomycin will receive daptomycin, and those who are allergic to beta-lactam drugs including cephalosporins will be given gentamicin. No intra-articular antibiotics will be routinely administered. All cultures will be followed until final. If cultures become positive, our institutional infectious disease (ID) department will be consulted for further recommendations and consideration for treatment.

Interventions

OTHERNot applicable- observational study

The investigators are only looking to see the rate of positivity of the cultures as well as what the organisms that are found in the cultures are.

Sponsors

University of Chicago
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (\>18 years old) with periprosthetic fractures around primary or revision hip or knee arthroplasty * Patients requiring operative management for these fractures (fixation or revision arthroplasty) * Patients presenting to the University of Chicago Medical Center during two (2) year period (October 2025 to October 2027)

Exclusion criteria

* Patients undergoing non-operative management for periprosthetic fractures * Any documented or reported history of past prosthetic joint infection of the involved joint * Sinus tract at the time of presentation at the involved joint

Design outcomes

Primary

MeasureTime frameDescription
Culture Positivity RatesFrom enrollment to the end of treatment at 14 days.This outcome measure is the percentage of cultures that grow organisms among the population

Secondary

MeasureTime frameDescription
Rate of ComplicationsFrom date of surgery to one year after the specific participant's surgery.Number of participants with surgery-related complications within one year after their surgeries.
Culture OrganismsFrom surgery date to 14 days after surgery.The names, number, and frequency of organisms being found in the cultures.
Treatments UsedFrom enrollment to one year after surgery.The list of antibiotics used for treating organisms found to be positive in the cultures.

Countries

United States

Contacts

Primary ContactMalik J Scott, BA
mjscott1@uchicago.edu773-834-0822
Backup ContactVincent Buckman, BS
vincent.buckman@uchicagomedicine.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026